巴巴贝病症被用Bimekizumab治疗
Matiar Madanchi1, Riccardo Curatolo1, Lorenzo S Pelloni2
1Department of Dermatology, University Hospital Basel, Basel, Switzerland.
The Australasian journal of dermatology
|October 11, 2025
概括
胡须脱发症 (sycosis barbae) 是一种胡须脱发症,可以用新型治疗方法比梅奇祖马布 (bimekizumab) 有效治疗,该新疗法向介质蛋白-17A和IL-17F. 这种治疗导致了耐火病例的完全缓解,提供了新的治疗选择.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
背景情况:
- 胡须 (sycosis barbae,简称SB) 是一种慢性,痕性脱毛症,影响胡须区域.
- 耐药病例带来了重大的治疗挑战.
研究的目的:
- 报告一个独特的耐火性Sycosis barbae病例.
- 评估比梅奇祖马布在治疗耐火性SB.SB.的疗效.
主要方法:
- 一名31岁的耐火性SB男性接受了比梅基祖马布治疗.
- 比梅基祖马布是一种双重抑制剂,可以抑制IL-17A (IL-17A) 和IL-17F (IL-17F).
主要成果:
- 在第二次bimikizumab注射后,观察到显著的临床改善.
- 在治疗4个月内,SB的完全缓解得到了实现.
结论:
- 比梅基祖马布显示出作为一种新型治疗方法的潜力,用于耐火性Sycosis barbae.
- 准IL-17A和IL-17F通路可能有利于SB管理.
相关概念视频
Skin Cancer
5.7K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
5.7K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
488
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
488
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
434
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
434
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
490
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
490


